Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT vs ADT for Oligometastatic Prostate Cancer
NCT04599686Unknown
- Sponsor
- Changhai Hospital
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Changhai Hospital. Primary endpoints: ADT-free survival at 1 year, Radiotherapy-related Toxicity at 1 year and 1 more. Status: unknown.
Beyond the preview
Go deeper on NCT04599686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599686.